LINEAGE CELL THERAPEUTICS, INC.

Analyst Reco. Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Market Closed - Nyse Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
1.13 ^USD	+3.67%		+2.73%	+3.67%

29/04	Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors	CI
11/03	Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Baird Starts Lineage Cell Therapeutics at Outperform With $5 Price Target	02/22/02	MT
B. Riley Initiates Lineage Cell Therapeutics at Buy with $4 Price Target, Says Platform, Pipeline Currently Undervalued	14/22/14	MT
LINEAGE CELL THERAPEUTICS : Noble Capital Initiates Coverage on Lineage Cell Therapeutics With Outperform Rating, $8 Price Target	19/21/19	MT
LINEAGE CELL THERAPEUTICS : Chardan Suspends Coverage on Lineage Cell Therapeutics at Buy Rating With $4 Price Target	02/21/02	MT
LINEAGE CELL THERAPEUTICS : Cantor Fitzgerald Starts Lineage Cell Therapeutics at Overweight With $6 Price Target	31/21/31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer